Steatosis News and Research

RSS

Regulating iron overload: Liraglutide's potential benefits

Researchers assess the role of liraglutide in regulating iron metabolism in a mouse model of hereditary hemochromatosis.

30 Sep 2024

The consumption of flavonoid-rich foods was associated with a reduced risk of NAFLD among middle-aged adults

Research indicates that high flavonoid intake is linked to a lower risk of NAFLD, with apples and tea showing significant protective effects on liver health.

30 Sep 2024

Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery

Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and non-modifiable factors, with key implications for disease biomarkers and drug targets.

30 Sep 2024

Liver receptor mutations linked to liver dysfunction, cholesterol accumulation, and hepatitis

Damaging LXRα variants are linked to liver cholesterol buildup and hepatitis, emphasizing the receptor's importance in cholesterol sensing and liver function.

27 Sep 2024

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

Targeted obesity programs reduce lipid-related heart disease risk in children

Researchers assess the lipid profiles of obese children and adolescents and their health implications.

24 Sep 2024

Higher soft drink consumption linked to increased risk of liver disease

Study found that higher soft drink consumption is associated with an increased risk of nonalcoholic fatty liver disease, especially in males, within a cohort of Mexican adults.

16 Sep 2024

Brazilian research uncovers how liver nerves regulate glucose production under stress

A study led by Brazilian researchers has produced a detailed description of the morphology of the nerves in the liver and how they control production of glucose when the organism is under stress.

11 Sep 2024

A promising new therapeutic target for MASLD identified

Using a novel stem cell platform, a team of the Medical University of South Carolina researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as metabolic dysfunction-associated steatotic liver disease, or MASLD.

11 Sep 2024

Camu-camu extract reduces liver fat in non-alcoholic fatty liver disease

A research team from Université Laval has shown the benefits of camu-camu on non-alcoholic fatty liver disease, which affects over seven million people in Canada.

21 Aug 2024

The real cost of processed foods: How Western diets are harming global health

A recent study in Nature Medicine reviews the adverse effects of Western diets on human health, highlighting increased risks of chronic diseases and gut dysbiosis. Researchers call for global awareness and promotion of healthier dietary patterns.

6 Aug 2024

Understanding the epigenetic regulation of hepatic stellate cells in NAFLD

Non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease worldwide, affecting approximately 38% of the global population from 2016 to 2019.

25 Jul 2024

Spinal Muscular Atrophy patients are at higher risk of developing fatty liver disease

An international study has discovered that people living with the neurodegenerative condition Spinal Muscular Atrophy (SMA) are at higher risk of developing fatty liver disease, suggesting that SMA patients may face additional health problems over time.

17 Jul 2024

CePA: Novel nanomedicine for alleviating MASH via mTOR repression

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses.

16 Jul 2024

Existing drug shows promise for treating common liver disease

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment.

11 Jul 2024